EcoR1 Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-6,000,000
Closed -$238M – 35
2026
Q1
$238M Buy
6,000,000
+2,885,000
+93% +$73.8M 10.11% 4
2025
Q4
$77.9M Buy
3,115,000
+2,565,000
+466% +$65M 3.53% 5
2025
Q3
$13.3M Buy
+550,000
New +$9.78M 0.64% 22
2024
Q4
– Sell
-3,223,851
Closed -$51.5M – 63
2024
Q3
$51.5M Sell
3,223,851
-2,490,553
-44% -$30.5M 1.76% 15
2024
Q2
$51.6M Buy
5,714,404
+95,625
+2% +$907K 1.58% 17
2024
Q1
$63.5M Hold
5,618,779
– – 1.61% 20
2023
Q4
$44.7M Hold
5,618,779
– – 1.16% 17
2023
Q3
$36.4M Hold
5,618,779
– – 1.23% 16
2023
Q2
$34.8M Hold
5,618,779
– – 0.85% 19
2023
Q1
$21.6M Buy
5,618,779
+386,500
+7% +$1.41M 0.7% 24
2022
Q4
$16.2M Buy
5,232,279
+1,995,927
+62% +$7.4M 0.49% 32
2022
Q3
$13M Buy
3,236,352
+2,944,032
+1,007% +$13.5M 0.38% 35
2022
Q2
$1.42M Sell
292,320
-162,225
-36% -$1.04M 0.05% 67
2022
Q1
$4.08M Sell
454,545
-427,631
-48% -$3.9M 0.13% 55
2021
Q4
$9.93M Buy
882,176
+127,631
+17% +$1.72M 0.32% 37
2021
Q3
$12.6M Hold
754,545
– – 0.44% 30
2021
Q2
$16.8M Buy
+754,545
New +$17.7M 0.63% 30

EcoR1 Capital's CNTA Position: Q2 2026 in Review

EcoR1 Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 6,000,000 shares — an estimated $238M sold.

EcoR1 Capital first reported a position in CNTA in Q2 2021 and held it in 17 quarters. The position peaked at $238M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • EcoR1 Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EcoR1 Capital sold 6,000,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $238M.
  • EcoR1 Capital first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 17 quarters.
  • EcoR1 Capital's Centessa Pharmaceuticals position peaked at $238M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.